共 50 条
- [41] CodeBreaK 200: A Phase 3 Multicenter Study of Sotorasib, a KRAS(G12C) Inhibitor, versus Docetaxel in Patients with Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC) Harboring KRAS p.G12C MutationJOURNAL OF THORACIC ONCOLOGY, 2021, 16 (01) : S29 - S29Reck, M.Spira, A.Besse, B.Wolf, J.Skoulidis, F.Borghaei, H.Goto, K.Park, K.Griesinger, F.Font, E. F.Boyer, M.Barrios, C. H.Goss, G.Yang, H.Obiozor, C.Ramalingam, S.
- [42] Clinical and genomic predictors of response and toxicity to sotorasib in a real-world cohort of patients with advanced KRAS G12C-mutant non-small cell lung cancerJOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)Arbour, Kathryn C.Thummalapalli, RohitBernstein, EzraHerzberg, BenjaminLi, Bob T.Iqbal, AfsheenSantini, Fernando CostaEng, JulianaLadanyi, MarcYang, Soo-RyumShen, RonglaiLito, PiroSabari, Joshua K.Riely, Gregory J.
- [43] Clinical and Genomic Features of Response and Toxicity to Sotorasib in a Real-World Cohort of Patients With Advanced KRAS G12C-Mutant Non-Small Cell Lung CancerJCO PRECISION ONCOLOGY, 2023, 7Thummalapalli, RohitBernstein, EzraHerzberg, BenjaminLi, Bob T.Iqbal, AfsheenPreeshagul, IsabelSantini, Fernando C.Eng, JulianaLadanyi, MarcYang, Soo-RyumShen, RonglaiLito, PiroRiely, Gregory J.Sabari, Joshua K.Arbour, Kathryn C.
- [44] Safety and Efficacy of D-1553 in Patients with KRAS G12C Mutated Non-Small Cell Lung Cancer: A Phase 1 TrialJOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S11 - S11Lu, S.Jian, H.Zhang, Y.Song, Z.Zhao, Y.Wang, P.Jiang, L.Gong, Y.Zhou, J.Dong, X.Yang, N.Fang, J.Zhuang, W.Cang, S.Ma, R.Shi, J.Wu, P.Lu, J.Xiang, Z.Shi, Z.Zhang, L.Wang, Y.
- [45] A real-world pharmacovigilance study of KRAS G12C mutation inhibitors based on the food and drug administration adverse event reporting systemFRONTIERS IN PHARMACOLOGY, 2024, 15Wu, LishaXu, MaoshengLi, XueqinAierken, DilinuerYu, JinxiuQin, Tao
- [46] Characterization of a cohort of metastatic lung cancer patients harboring KRAS mutations treated with immunotherapy: differences according to KRAS G12C vs. non-G12CFRONTIERS IN ONCOLOGY, 2023, 13Notario, LuciaCucurull, MarcCerda, GabrielaSanz, CarolinaCarcereny, EnricMunoz-Marmol, AnaHernandez, AinhoaDomenech, MartaMoran, TeresaSanchez-Cespedes, MontseCosta, MartaMate, Jose-LuisEsteve, AnnaSaigi, Maria
- [47] Treatment and outcome of a real-world cohort of patients with advanced, non-squamous NSCLC and KRAS mutations with a special focus on KRAS G12CONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 135 - 135Griesinger, F.Eberhardt, W.Hoffknecht, P.Metzenmacher, M.Wehler, T.Kokowski, K.Alt, J.Schuette, W.Jaenicke, M.Fleitz, A.Zacharias, S.Hipper, A.Buller, M.Weichert, W.Groschek, M.von der Heyde, E.Rauh, J.Dechow, T.Sebastian, M.Thomas, M.
- [48] Sotorasib treatment in KRAS G12C-mutated non-small cell lung cancer: Experience in the Tours university hospitalREVUE DES MALADIES RESPIRATOIRES, 2023, 40 (01) : 17 - 23Bessy, C.Blin, T.Pichon, E.Marchand-Adam, S.Carmier, D.
- [49] Real-world retrospective study of KRAS mutations in advanced nonsmall cell lung cancer in the era of immunotherapyCANCER, 2023, 129 (11) : 1662 - 1671Bironzo, PaoloCani, MassimilianoJacobs, FrancescaNapoli, Valerio M.Listi, AngelaPassiglia, FrancescoRighi, LuisellaDi Maio, MassimoNovello, SilviaScagliotti, Giorgio, V
- [50] Treatment and outcome of a real-world cohort of patients with advanced, non-squamous NSCLC and KRAS mutations with a special focus on KRAS G12CANNALS OF ONCOLOGY, 2020, 31 : S872 - S872Griesinger, F.Eberhardt, W. E. E.Hoffknecht, P.Metzenmacher, M.Wehler, T.Kokowski, K.Alt, J.Schuette, W.Jaenicke, M.Fleitz, A.Zacharias, S.Hipper, A.Buller, M.Weichert, W.Groschek, M.von der Heyde, E.Rauh, J.Dechow, T.Sebastian, M.Thomas, M.